{"type":"rich","version":"1.0","title":"Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline","description":"In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV).\n\nTopics covered:\nWhy fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to change\nThe diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementation\nThe recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question\n10 mg vs. 2 mg dose considerations and off-treatment response data\nPhase 3 pipeline\n\nFor more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline","author_name":"HCPLive Podcasts","author_url":"https://audioboom.com/channels/5004077-hcplive-podcasts","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43734537/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}